BioCina aims for vaccines against biowarfare threats
Vaccine maker BioCina is partnering with defence and university researchers on a project to create immunisations against biological warfare agents including Q Fever, tularaemia and melioidosis.
Company
Every investor coverage indicates participated in a round DMTC raised.
Companies DMTC acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Mark Hodge | CEO | @AuManufacturing |
Stories naming DMTC. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Vaccine maker BioCina is partnering with defence and university researchers on a project to create immunisations against biological warfare agents including Q Fever, tularaemia and melioidosis.
Stress-imaging startup 1Millikelvin won two innovation awards at the Avalon airshow, including a $50,000 SME prize, with individual and commendation awards going to BAE Systems, MicroTau and RMIT-affiliated researchers.
Quickstep is partnering with Defence researchers, DMTC and UNSW on the Hype-X project to develop heat-resistant composite materials for hypersonic aircraft structures, with commercialisation rights to new intellectual property.